Observational Study
Copyright ©The Author(s) 2024.
World J Psychiatry. Sep 19, 2024; 14(9): 1354-1363
Published online Sep 19, 2024. doi: 10.5498/wjp.v14.i9.1354
Table 1 Primer sequences for miR-124, miR-132, and U6
Gene
PCR primer sequences
miR-124Forward: 5’-GCGGTGAATGCCAAAAA-3’
Reverse: 5’-CGCAAGGATGACACGCAAATTCGT-3’
miR-132Forward: 5’-ACCGTGGCTTTCGATTGTTA-3’
Reverse: 5’-GGCGACCATGGCTGTAGACT-3’
U6Forward: 5’-TTGTGGAAAGGACGAAACAC-3
Reverse: 5'-GGCCATGCTAATCTTCTG- 3'
Table 2 Comparison of baseline characteristics between the two groups
Characteristic
Experimental group (n = 30)
Control group (n = 30)
P value
Age (year)60.07 ± 4.8961.79 ± 4.530.232
BMI (kg/m2)23.92 ± 2.1424.08 ± 2.670.768
Males (%)46.756.70.436
< 2 stents (%)63.353.30.432
≥ 2 stents (%)36.746.70.432
Table 3 Comparison of depression treatment effectiveness
Group
Experimental
Control
χ2
P value
Number of cases3030
Clinical control, n (%)9 (30.00)6 (20.00)
Significant effect, n (%)11 (36.67)14 (46.67)
Effective, n (%)8 (26.67)7 (23.33)
Ineffective, n (%)2 (6.67)3 (10.00)
Total, effectiveness rate n (%)28 (93.33)27 (90.00)0.2180.640
Table 4 Paired t-test analysis of 17-item Hamilton Rating Scale for Depression score
Characteristic
Experimental group (n = 30)
Control group (n = 30)
P value
Age (year)60.07 ± 4.8961.79 ± 4.530.232
BMI (kg/m2)23.92 ± 2.1424.08 ± 2.670.768
Males (%)46.756.70.436
< 2 stents (%)63.353.30.432
≥ 2 stents (%)36.746.70.432
Table 5 Comparison of traditional Chinese medicine syndrome scores in depression (mean ± SD, points)
GroupNumber of casesMain symptoms
Secondary symptoms
Before treatment
After treatment
Before treatment
After treatment
Experimental309.51 ± 2.093.12 ± 0.93a7.06 ± 1.272.84 ± 0.64a
Control309.32 ± 2.014.63 ± 1.09a7.14 ± 1.353.49 ± 0.72a
t0.3595.7720.2363.696
P value0.721< 0.0010.8140.001
Table 6 Comparison of biochemical indicators between the two groups (mean ± SD, n = 30)
Group
Experimental
Control
t
P value
LDL-C (mmol/L)
Before treatment3.21 ± 0.873.35 ± 0.680.6940.490
After treatment1.61 ± 0.66a1.97 ± 0.63a2.1610.035
hs-CRP (mg/L)
Before treatment8.47 ± 1.238.89 ± 1.561.1570.252
After treatment5.67 ± 0.59a6.25 ± 0.67a3.5580.001
BDNF (ng/mL)
Before treatment4.29 ± 0.974.58 ± 0.881.2130.230
After treatment13.71 ± 3.16a10.43 ± 3.93a3.5630.001
miR-124
Before treatment0.89 ± 0.250.93 ± 0.260.6070.546
After treatment1.22 ± 0.30a1.01 ± 0.27a2.8500.006
miR-132
Before treatment3.39 ± 0.783.22 ± 0.740.8660.390
After treatment1.41 ± 0.36a1.73 ± 0.49a2.8830.006
Table 7 Comparison of lymphocyte subgroup indicators between the two groups (mean ± SD, n = 30)
Group
Experimental
Control
t
P value
CD3+T cells
Before treatment53.45 ± 4.5652.13 ± 5.110.9240.568
After treatment69.89 ± 5.03a,b58.32 ± 5.25a4.8570.012
CD3+CD4+Th cells
Before treatment29.23 ± 3.2828.65 ± 3.420.8740.646
After treatment40.05 ± 3.96a,b32.35 ± 4.17a5.2310.009
CD3+CD8+CTL cells
Before treatment25.34 ± 2.9226.76 ± 2.870.9220.0324
After treatment20.19 ± 3.1824.24 ± 3.620.8450.425
CD3-CD19+B cells
Before treatment14.85 ± 2.3312.56 ± 2.120.9840.266
After treatment10.63 ± 2.9615.32 ± 3.331.0110.123
CD3-CD56+16+NK cells
Before treatment11.45 ± 2.9112.77 ± 3.040.6510.758
After treatment15.66 ± 3.05a13.46 ± 3.123.8640.011
Table 8 Comparison of the incidence rates of adverse reactions in two groups (cases)
Group
Experimental
Control
Fisher P value
Number of cases3030
Abdominal pain, n (%)0 (0.00)2 (6.67)
Nausea, n (%)0 (0.00)2 (6.67)
Vomiting, n (%)0 (0.00)1 (3.33)
Total incidence, n (%)0 (0.00)5 (16.67)0.020